<--- Back to Details
First PageDocument Content
Anatomical pathology / Basal-cell carcinoma / Histopathology / Skin cancer / Nevoid basal cell carcinoma syndrome / Vismodegib / Melanoma / Skin Cancer Foundation / Cancer / Medicine / Oncology / Carcinoma
Date: 2013-07-08 10:50:29
Anatomical pathology
Basal-cell carcinoma
Histopathology
Skin cancer
Nevoid basal cell carcinoma syndrome
Vismodegib
Melanoma
Skin Cancer Foundation
Cancer
Medicine
Oncology
Carcinoma

Microsoft Word - Advanced Basal Cell Carcinoma

Add to Reading List

Source URL: www.roche.com

Download Document from Source Website

File Size: 91,05 KB

Share Document on Facebook

Similar Documents

article published online: 8 january 2012 | doi: nchembio.765 Oxysterols are allosteric activators of the oncoprotein Smoothened

article published online: 8 january 2012 | doi: nchembio.765 Oxysterols are allosteric activators of the oncoprotein Smoothened

DocID: 1kIJA - View Document

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6

DocID: 1gamh - View Document

Vismodegib, a Hedgehog Pathway Inhibitor, in Advanced Basal Cell Carcinoma: STEVIE Study Interim Analysis in 300 Patients Jean-Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Thomas Jouary, Laurent Mortier, Paolo A. Asc

Vismodegib, a Hedgehog Pathway Inhibitor, in Advanced Basal Cell Carcinoma: STEVIE Study Interim Analysis in 300 Patients Jean-Jacques Grob, Rainer Kunstfeld, Brigitte Dréno, Thomas Jouary, Laurent Mortier, Paolo A. Asc

DocID: 1cKRW - View Document

8579  Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC): ERIVANCE BCC Study Update Aleksandar Sekulic,1 Michael R Migden,2 Anthony E Oro,3 Karl Lewis,4

8579 Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC): ERIVANCE BCC Study Update Aleksandar Sekulic,1 Michael R Migden,2 Anthony E Oro,3 Karl Lewis,4

DocID: 1clpL - View Document

Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G

Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G

DocID: 1axH7 - View Document